Tau phosphorylation and aggregation in Alzheimer’s disease pathology  by Avila, Jesús
FEBS Letters 580 (2006) 2922–2927Minireview
Tau phosphorylation and aggregation in Alzheimer’s disease pathology
Jesu´s Avila*
Centro de Biologı´a Molecular ‘‘Severo Ochoa’’ (CSIC-UAM), Cantoblanco, Universidad Auto´noma de Madrid, 28049 Madrid, Spain
Received 3 February 2006; revised 22 February 2006; accepted 25 February 2006
Available online 3 March 2006
Edited by Horst FeldmannAbstract In this article I shall review how tau phosphorylation
and aggregation participates in Alzheimer’s disease (AD) and
other tauopathies. Tau, a microtubule associated protein, is the
main component, in phosphorylated form, of the aberrant paired
helical ﬁlaments found in AD. Tau is present in phosphorylated
and aggregated form not only in AD, but in other pathologies
(tauopathies). In this review, the phosphorylation of tau, its
aggregation, and the possible relation between tau phosphoryla-
tion and aggregation is, brieﬂy, described. Also, it is discussed
the toxicity of modiﬁed tau. In addition, I propose a working
model detailing the progression of tau pathologies.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Tau protein was ﬁrst discovered as a microtubule associated
protein that lowered the concentration at which tubulin poly-
merizes into microtubules in the brain [1]. Subsequently, two
additional consequences of tau binding to neural microtubules
were identiﬁed, a positive and a negative one. The positive ef-
fect of tau is to stabilize assembled microtubules permitting
neurite extension and stabilization [2,3]. The negative eﬀect is
that tau competes with the motor protein kinesin for microtu-
bule binding [4–6], leading to a decrease in axonal transport
[4–6]. It is possible that an equilibrium between these two ef-
fects is necessary for correct axonal transport via stable micro-
tubules. Nevertheless, proteins other than tau may also be
involved in these processes since mice lacking tau do not dis-
play important diﬀerences with respect to wild type mice [7,8].
Some twenty years ago, additional interest in the tau protein
arose when it was identiﬁed as a component of the paired heli-
cal ﬁlaments (PHFs) in 1986 [9]. PHFs contribute to neuroﬁ-
brillary tangles (NFT), protein aggregates that along with
senile plaques, are the aberrant structures found in the brains
of patients with Alzheimer’s disease (AD) [10]. At virtually theAbbreviations: AD, Alzheimer’s disease; PHF, paired helical ﬁlaments;
FTDP-17, frontotemporal dementia and parkinsonism linked to chr-
omosome 17; PSP, progressive supranuclear palsy; CBD, corticobasal
dementia; NFT, neuroﬁbrillary tangles
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doi:10.1016/j.febslet.2006.02.067same time, it was further shown that tau was probably the
main component of PHFs since it alone was able to form
PHF-like structures [11]. The contribution of Tau to PHFs
was further conﬁrmed in elegant biochemical studies [12,13],
and PHF-tau was demonstrated to exist in a hyperphosphoryl-
ated form [14]. Indeed, tau hyperphosphorylation was pro-
voked a decrease in the binding of tau to microtubules [15].
Diﬀerent isoforms of the tau protein can be expressed as the
result of diﬀerential RNA splicing and each of these displays a
diﬀerent degree of phosphorylation [16,17]. All the isoforms
are capable of polymerizing into ﬁbrillar structures [18] such
as those present in AD. Signiﬁcantly, tau polymers can also
be found in other neurodegenerative disorders characterized
by the presence of phosphotau aggregates, the so-called tauop-
athies [19]. Thus, the pathologies associated with tau are re-
lated to its phosphorylation and its aggregation, the two
points on which this review will be focused.2. Tau phosphorylation
The serine/threonine phosphorylation of tau is a modiﬁca-
tion that can aﬀect a total of 79 residues in the longest tau iso-
form in the central nervous system of 441 residues [20], and it is
that which has been most studied. In AD, at least thirty serine/
threonine residues are phosphorylated [21,22] by two diﬀerent
types of kinases: proline directed kinases, like GSK3, cdk5,
p38 or JNK; and non-proline directed kinases, like PKA,
PKC, CaMKII, MARK or CKII [22–31]. Moreover, it appears
that this phosphorylation often regulates the binding of tau to
microtubules [15]. Among the kinases identiﬁed above, GSK3
plays an important role in regulating tau phosphorylation un-
der pathological conditions. Indeed, a link between tau phos-
phorylation, by GSK3, and the formation of aberrant tau
aggregates has been established in certain mouse models
[32,33]. There is also evidence that pseudohyperphosphorylated
tau is toxic to cells and that is associated with the induction of
apoptotic cell death [34]. Indeed, since phosphorylated tau ap-
pears to be more resistant to proteolysis by diﬀerent proteases
[35,36], this phosphotau could accumulate in neurons, thereby
exerting its toxic inﬂuence on the cell.3. Tau phosphorylation by GSK3 in FAD
A particular class of AD, familiar AD (FAD), is associated
with mutations in the genes app, ps-1 and ps-2 [37], which are
responsible for the expression of the proteins APP, PS-1 and
PS-2. APP is the protein precursor for the main componentblished by Elsevier B.V. All rights reserved.
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Fig. 1. Tau phosphorylation promoted by PS-1 mutations. PS-1 is a
protein present in the c-secretase complex that can also bind to
cadherins and to the regulatory subunit of PI3K. Mutations in PS-1
could result in an increase of c-secretase activity and may promote an
increase in the amount of beta amyloid peptide and in GSK3 activity.
As a consequence tau phosphorylation will increase. In contrast, other
PS-1 mutations, or the lack of PS-1, may diminish PI3K activity, also
resulting in an increase in GSK3 activity and in tau phosphorylation.
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and PS-2 are components of a protein complex that displays
proteolytic activity and that is involved in the cleavage of
APP to yield Ab. The current hypothesis, the Ab cascade
hypothesis [38], proposes that the accumulation of Ab may
be augmented by mutations in APP that facilitate its cleavage
to Ab. Alternatively, it has been suggested that gain of func-
tion mutations might increase the activity of the protease com-
plex in which PS-1 or PS-2 participates, thereby augmenting its
activity towards APP and the production of the Ab peptide.
The accumulation of Ab in turn facilitates tau phosphoryla-
tion by kinases like GSK3 [39].
However, the validity of this hypothesis has been recently
been questioned, since pathological tau isoforms (phosphory-
lated tau) can accumulate in the absence of the Ab peptide. In-
deed, there is a neurological disorder that appears to be
promoted by mutations in PS-1 [40,41], mutations that result
in tau hyperphosphorylation in the absence of Ab aggregates
[42]. Thus, diﬀerent mutations in FAD associated genes, such
as PS-1, can produce either a gain or loss of function that facil-
itate tau phosphorylation (see Fig. 1), a main feature of AD
and other tauopathies. Accordingly, tau is hyperphosphoryl-
ated in other tauopathies and in some of these disorders, like
frontotemporal dementia and parkinsonism linked to chromo-
some 17 (FTDP-17), progressive supranuclear palsy (PSP) or
corticobasal dementia (CBD), mutations in the tau protein it-
self appear to facilitate its phosphorylation, aggregation, and
the onset of the disease [19].4. How is tau phosphorylated in other tauopathies like FTDP-17
A familiar form of FTDP-17 has been related to alterations
of chromosome 17, in the q 21.2 region [43]. This is the locus of
the tau gene and mutations in this gene have been associated
with FTDP-17 in some patients [19]. These mutations proved
to be either missense, deletions, or silent mutations in exons
or introns, and they might aﬀect tau RNA splicing [44]. One
consequence of these mutations may be a loss of the capacityto bind PP2A, the protein phosphatase that is mainly respon-
sible for the dephosphorylation of phosphotau [45]. This
would result in the accumulation of this mutated and phos-
phorylated tau, since it will not be dephosphorylated. In other
tauopathies linked to mutations in tau like PSP or CBD, an
association has also been made between the phosphorylation
of the protein and the onset of the disease [19,44].5. Tau aggregation
5.1. In vitro
As indicated above, the assembly of the tau protein into
ﬁbrillar polymers resembling the PHF found in the brain of
AD patients in vitro was ﬁrst described in 1986 [11]. However,
a large amount of tau was required to produce polymerization
in vitro [7,11,46,47]. Nevertheless, the minimum tau concentra-
tion needed for its assembly could be lowered in the presence
of inducers, an eﬀect that has been attributed to sulfoglycosa-
minoglycans, like heparin, which facilitate tau polymerization
in vitro [48,49]. Similarly, fatty acids like arachidonic acid (or
its peroxidation products [50]) can induce tau polymerization
in vitro [51] and more recently, quinones such as CoQ0, have
been shown to induce tau polymerization [52]. The minimum
region required for tau self-assembly has been mapped to the
third tubulin binding motif of the tau molecule [49,53] and
within this motif, two peptides have been implicated in self-
assembly. Speciﬁcally, these involve a peptide containing resi-
dues 306–301 (peptide 1) that is able to self-assemble in the
absence of any added compound [53] and a peptide containing
residues 317–335 (peptide 2) [49]. Characterization of tau vari-
ants lacking either of these peptides indicated that while pep-
tide 1 facilitates tau assembly, it is not essential. In contrast,
the presence of peptide 2 is a requisite for tau polymerization
in the presence of quinones (Santa-Maria et al., to be pub-
lished). A model to explain the inﬂuence of both peptides in
promoting ﬁlament formation has recently been proposed
[54]. In this model, it is suggested that tau will only assemble
after these two peptides undergo a conformational change,
P1 forming a b-sheet structure and P2 an a-helix [54].
5.2. In vivo
In mice, two approaches have been followed to mimic the
AD [55] or FTDP17 (see for example [56,57]) tauopathies. In
the ﬁrst case, human tau was overexpressed in a mouse lacking
the endogenous tau protein [55] while in the second model, hu-
man tau protein bearing some of the mutations found in
FTDP17 patients was expressed in mice [56,57]. In both cases,
hyperphosphorylated tau ﬁlaments were generated. In the
mouse model of the AD tauopathy, human tau expression
was driven by its own promoter, whereas in FTDP17 model,
tau was expressed under diﬀerent promoters that controlled
the expression of tau (and the pathology) in neurons at diﬀer-
ent locations [58]. It has been suggested that the onset of dis-
tinct tauopathies in diﬀerent localizations could be due to
variations in environmental conditions, or related to diﬀerent
tau mutations. Indeed, in some cases, the presence of diﬀerent
tau variants could play a role in the formation of tau polymers
in distinct types of neurons. Hence, Goedert suggested [44] that
changes in the ﬁrst tubulin binding motif of the tau molecule
could be related to the onset of Pick’s disease, whereas changes
in the C-terminal domain of the tau molecule could be related
2924 J. Avila / FEBS Letters 580 (2006) 2922–2927to the onset of AD. Similarly, changes in 4R/3R ratio could
promote the appearance of CBD or PSP.
5.3. Are tau aggregates toxic?
The discovery of mutations in the tau gene that promote
familiar FTDP-17, provided clear evidence that defects in
tau alone are suﬃcient to cause neurodegenerative disorders
[59–61]. As indicated above, tau pathologies can be reproduced
in speciﬁc locations of the mouse brain by expressing human
tau driven by diﬀerent promoters. However, tau pathology in
AD follows a clear and speciﬁc kinetic pathway that does
not usually correspond to that found in animal models. Some
time ago, the diﬀerent stages of tau pathology in AD were de-
scribed by Braak and Braak [62] and more recently, a similar
description was made by Delacourte et al. [63]. Tau pathology
starts in the entorhinal cortex (EC), from where it spreads to
neighbouring regions, like the hippocampus (Fig. 2). Neurode-
generation was found in these regions and as a consequence,
extracellular ghost tangles (eNFT) could be observed as de-
scribed in the pioneer work of Alzheimer [10]. In the hippo-
campus, an inverse relation has been found between the
number of eNFT and the number of surviving neurons [64–
66]. Thus, this data would suggest that the neurons which
degenerate previously develop tau aggregates. Recent experi-
ments done in cultured cells, expressing tau protein fragments
[67] support that view. That degeneration could be related to a
possible sequestration, by the sticky tau aggregates, of diﬀerent
proteins important for cell function [68,69]. On the other hand,
it is clear that the degeneration of neurons could also result in
the appearance of extracellular unpolymerized tau, which
could ﬁnally be found in the cerebrospinal ﬂuid of AD patients
[70]. Nevertheless, it has also been proposed that neurons bear-
ing neuroﬁbrillary lesions could survive for long periods of
time, and it has been suggested that these aggregates mayEntorhinal
region
Subiculum
Fig. 2. Progress of tau pathology in AD. The scheme, ﬁrst indicated by B
entorhinal cortex and its spreading to neighbouring regions from that pointnot be toxic but rather that they could protect against degen-
eration in a similar way to the aggregates found in Hunting-
ton’s disease [71]. Accordingly, it has been proposed that tau
aggregates might protect against neurodegeneration by seques-
tering the toxic phosphotau that accumulates in a neuron un-
der pathological conditions [72]. More recently, it was shown
that the memory defects observed in a transgenic mouse model
in which tau ﬁlaments accumulate were unrelated to the pres-
ence of those tau polymers [73], a result that agrees well with
previous experimental data from Drosophila [74]. In contrast,
it was suggested that intermediate tau aggregates, rather than
PHF-like structures could be involved in neurodegeneration
[75]. Native tau can be found in the form of small oligomers
[76]. Furthermore, the fact that FTDP-17 patients suﬀer exten-
sive neurodegeneration with a high level of tau phosphoryla-
tion but with few tangles, also supports the possible
existence of toxic, modiﬁed tau in human tauopathies [77].
Our preliminary results (Gomez-Ramos et al., to be pub-
lished), suggest that some tau proteins are toxic to cultured
neuronal cells, and that such toxicity could change upon tau
aggregation.
5.4. A working model
Taking into account all the data reviewed above, I propose a
working model to explain the spreading of tau pathologies.
This model is based on the fact that tau, when is not bound
to microtubules, or is in modiﬁed form, is toxic to neuronal
cells. In AD, the tau pathology starts in the entorhinal cortex.
If the probability of neuron death in this region were similar to
that in other regions, it might be possible to explain the onset
of the tau pathology in the EC if the EC cells were to have a
lower proportion of their tau bound to microtubules, or in
modiﬁed form. Indeed, a lower aﬃnity for tau to microtubules
in entorhinal neurons has already been proposed [78]. ThroughTrans-
entorhinal
region
raak and Braak [62], shows the initiation of the tau pathology in the
.
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bound to microtubules, or in modiﬁed form, that enters the
extracellular space would augment, and that could in turn
interact with and be taken up by other neurons. The ensuing
degeneration of these neurons would again release the tau,
and more extracellular tau will be available to exert a toxic ef-
fect on other neurons. This process could be repeated period-
ically, establishing a type of chain reaction that would result in
the spread of the tau pathology.
In essence, this model involves two steps: the initiation of the
pathology and its spreading. In AD, initiationmay be due to the
toxic eﬀect of the beta amyloid peptide, particularly if we take
into account the amyloid cascade hypothesis [38]. The distribu-
tion of beta amyloid aggregates varies widely across diﬀerent
brain regions [62] and the presence of such aggregates in the
EC could promote local neurodegeneration in a region where
alsomutations of PS-1would further enhance neuronal loss [79].
In the case of familiar FTDP-17, it is possible that an un-
known factor could initiate the degeneration of neurons in
any brain region. Since a higher proportion of tau is expressed
in the frontotemporal region [80] and it is in a mutated (un-
bound to microtubules, or in modiﬁed form) form in familiar
FTDP-17, the probability that the pathology will progress
would be higher in that area.
In those tauopathies, a possible change in the interaction of
tau (unbound to microtubules) to internal membranes [81,82],
could not be excluded.
For the second step, the rate at which the tau pathology
spreads will depend on the neural death promoted by the pres-
ence of extracellular tau protein, toxic to neurons. Thus, while
our model suggests a pathological role for extracellular tau,
there is still much work to be carried to fully understand
how tau pathology initiates in AD.
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